in the marrow. The possible relevance of these findings to the treatment of GS post-BMT is also discussed.
with grade I GVHD, which was successfully treated. No ination of the biopsied tissues showed characteristic features of GS, with extensive infiltration by myeloblasts conchronic GVHD occurred. One year post-BMT, she presented with a left breast GS that responded to RT. CT firmed by expression of myeloperoxidase. In case 1, staining for CD56 (N-CAM) was strongly positive in the scan of the abdomen also showed a 5-cm left adnexal mass. Despite 2% of blasts in the blood, the BM biopsy was norblast cells in the pancreatic and cerebral biopsies, but was negative in the initial relapsed marrow before BMT. Stainmal. A second BMT from an HLA-identical brother was performed with melphalan (140 mg/m 2 )-TBI as conditioning for CD56 was negative in the GS of cases 2 and 3. In case 1, during one episode of concomitant disseminated GS ing. She engrafted with grade II acute GVHD and mild chronic GVHD of the skin. Four years after the second in the brain, breast and thigh, FISH analysis of the peripheral blood showed about 3% recipient cells, consistent with BMT she developed recurrent GS of the skin, which was partially controlled by intermittent Ara-C and TG. Two the morphologic finding of occasional circulating blasts. Interestingly, the marrow was still in remission and popudonor lymphocyte infusions resulted in grade II GVHD of the skin but no effect on the GS. Six months later, obstruclated by donor cells. Analysis of a fine needle aspirate from the GS in the thigh showed that most of the blasts were of tive jaundice developed and a pancreatic mass was demonstrated by CT scanning, which responded to RT. She is recipient origin (Figure 1) , with infiltrating white cells of donor origin. In case 2, with multiple GS recurring, convencurrently well with persisting skin lesions.
tional cytogenetics as well as FISH did not show any evidence of marrow recurrence. In case 3, the marrow was Case 3: A 40-year-old man with AML M1 relapsed 1 year still in morphologic remission at the terminal stage, and after first CR, and entered a second CR with salvage populated predominantly by donor cells with only about chemotherapy. He relapsed again a few months later and 5% of recipient cells (Table 1) . RT-PCR did not show the entered a third CR. Allogeneic BMT from an HLA-matched presence of AML1/ETO in any of the cases (data not unrelated female donor was performed, with Bu-CY-TBI shown). as conditioning and CsA and MTX as GVHD prophylaxis. Grade II GVHD of the skin and liver developed and was treated with CsA and steroids. Nineteen months post-BMT Discussion a testicular mass developed, which was confirmed to be GS on orchiectomy. Local RT was given. This was followed Granulocytic sarcoma (GS) can be a presenting feature or by multiple GS in the axillae, chest wall, left thigh and complication of AML, myelodysplasia or chronic myeloid neck. RT and intermittent Ara-C/TG were administered. At leukemia. 7 The reason for the propensity of the blast cells 26 months post-BMT, multiple biopsy proven gastric and to infiltrate tissue is unknown but the two most commonly colonic GS developed, followed by masses in the bladder, reported associations are the expression of the surface skin and hepatic portal area. He finally died of intestinal antigen CD56 and the presence of t(8;21). 7 bleeding 1 month afterwards. GS is a rare complication of AML patients post-BMT. In a recent review by the European Group for Blood and Histologic, cytogenetic, fluorescence in situ hybridization Marrow Transplantation (EBMT), 3 GS was found in 20 and molecular studies (0.65%) of 3071 patients. In all but one of these patients, GS was accompanied by marrow relapses after 1 to 12 Bone marrow examination was based on standard morphomonths, with the median survival at a mere 10 months. logic criteria. Hematoxylin and eosin slides were prepared Our three cases were among 16 cases of relapses from a from the paraffin-embedded marrow trephine and the GS consecutive series of 84 AML patients receiving allogeneic biopsies, and immunohistochemical staining was performed BMT (unpublished data), giving a rather high frequency of by the standard avidin-biotin complex method. A poly-3.6%. This higher frequency might be due to case selection clonal antibody directed against myeloperoxidase (Dako, for BMT, as well as the conditioning regimen and postGlostrup, Denmark) was used for confirmation of the BMT graft-versus-host disease prophylaxis. The biologic myeloid nature of the blasts. For the monoclonal CD56 basis for the occurrence of GS remains obscure. Expression antibody (Monosan, Uden, The Netherlands), a pressure of CD56 on the leukemic cells has been regarded as concooker was employed for antigen retrieval. 4 Cytogenetic tributory. CD56 is found in many body tissues and the molanalysis was performed on fluorodeoxyuridineecule is known to form dimers, which may account partly synchronized overnight culture of marrow cells. Fluorfor 'homing' of the leukemic cells to sites expressing escence in situ hybridization (FISH) with a chromosome CD56. 8 Expression of CD56 was only found in one of our X specific centromeric probe was performed as previously cases, showing that this is not the only mechanism for GS described. 5 Reverse transcription polymerase chain reaction formation. Finally, although our cases and indeed most of (RT-PCR) for AML1/ETO was performed as reported. 6 the other reported cases of GS did not have data to show identity to the original leukemias, it is unlikely that they represent secondary malignancies, as these usually occur Results after a long latent period, and secondary leukemias post-BMT are very uncommon.
9,10
Histologic, cytogenetic, FISH and molecular studies The unique differences between our series and those of the EBMT are the absence of marrow relapses, and the None of the cases showed morphologic evidence of marrow relapse at any stage of their GS (Table 1) . Histologic examunusually long survival of these cases despite repeated GS GS post-BMT, as was shown in our cases and few other reported cases, the clinical course was indolent, with a good response to local radiotherapy and an absence of medullary relapse. Rare cases might actually be cured by local treatment only. 3 The absence of marrow relapse, and the potential curability of some cases of GS post-BMT by local therapy alone underline the importance of a GVL that prevents the establishment of chimeric hematopoiesis in the marrow. Cells responsible for the putative GVL effect, ie CD8-positive T cells and natural killer cells, are known to be present in much higher numbers in the marrow than in the peripheral tissues. 12 The other possibility is a lack of a suitable milieu of cytokines or other molecules 3 in the peripheral tissues for the GVL effector cells to function maximally.
Finally, our observations may have potential implications for the treatment of isolated GS post-BMT. As most cases ment (chemotherapy or donor lymphocyte infusion 13 ) should be administered. However, if the presence of donor hematopoiesis and the absence of marrow leukemic relapsing in different sites. This is in contrast to the dismal relapses can be demonstrated by sensitive methods such as prognosis of medullary relapse of AML post-BMT, where molecular genetic techniques or FISH, implying that a GVL chemotherapy or a second BMT are generally ineffective. 11 effect may still be present, local treatments of GS in combiFurthermore, the GS in our cases appeared to behave differnation with an augmentation of the GVL effect (eg by ently from GS complicating AML. In the latter cases, the donor lymphocyte infusion 13 ) may be tried to avoid the GS is usually highly aggressive and local treatment alone is followed invariably by marrow relapses. 7 However, in potential toxicities of chemotherapy. On the other hand, if
